- products will be manufactured by U.S.-based Med-Pharmex Inc. -
BELLEVILLE, ON, Aug. 20, 2012 /CNW/ - Bioniche Life Sciences Inc. (TSX: BNC) (ASX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today announced that it has launched a new product in the U.S. - ButequineTM Paste (phenylbutazone paste) - for the relief of inflammatory conditions associated with the musculoskeletal system in horses. This is a proprietary product of Bioniche that is manufactured by Med-Pharmex Inc., a U.S.-based contract manufacturer.
Bioniche has also acquired exclusive Canadian distribution rights to an additional six products from Med-Pharmex, including topical Dermal products for dogs and cats, an anti-diarrheal product for dogs, cats, horses and cattle, and nutritional supplements for calves. Med-Pharmex will manufacture all of these products for Bioniche.
About ButequineTM Paste
ButequineTM Paste is an FDA-approved product for horses that is administered orally by syringe. Phenylbutazone is a non-steroidal anti-inflammatory drug (NSAID). The product has a dose volume which is easy to administer, and it is cost-competitive. Its green apple flavour is palatable and easily ingested by horses.
"Bioniche Animal Health has been selling this product successfully in Canada for several years," said Mr. Andrew Grant, President of Bioniche Animal Health (global). "We expect U.S. equine veterinarians to be very receptive to ButequineTM Paste, and we expect to see significant market penetration over the next two years."
About the Med-Pharmex Products for Canada
Bioniche will be registering and selling six new Med-Pharmex products in Canada. "Once registered, these products will become important additions to the Bioniche Animal Health product line for both large and small animal veterinarians as they are high-volume, high-value products that are used in everyday veterinary care," said Mr. Grant.
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven Canadian biopharmaceutical company focused on the discovery, development, manufacturing, and marketing of proprietary and innovative products for human and animal health markets worldwide. The fully-integrated company employs more than 200 skilled personnel and has three operating divisions: Human Health, Animal Health, and Food Safety. The Company's primary goal is to develop and commercialize products that advance human or animal health and increase shareholder value.
Bioniche Animal Health develops, manufactures and markets veterinary biopharmaceutical products worldwide. In North America, it has development, manufacturing and marketing facilities in Belleville, Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington, U.S.A. In Australia, business is conducted from two sites: Sydney, New South Wales, where sales and marketing, customer support and technical service are located; and Armidale, New South Wales, where research, development and manufacturing facilities are located.
Bioniche Life Sciences Inc. has been named one of the Top 50 Best Small and Medium-Sized Employers in Canada for 2011. For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process, and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.
SOURCE: Bioniche Life Sciences Inc.
For further information:
Jennifer Shea, Vice-President, Communications, Investor & Government Relations
Bioniche Life Sciences Inc.
Telephone: (613) 966-8058; from Australia: 0011 1 613-966-8058
Cell: (613) 391-2097; from Australia: 0011 1 613-391-2097